CN116568289A - 治疗勃起功能障碍的配方和方法 - Google Patents

治疗勃起功能障碍的配方和方法 Download PDF

Info

Publication number
CN116568289A
CN116568289A CN202180076999.6A CN202180076999A CN116568289A CN 116568289 A CN116568289 A CN 116568289A CN 202180076999 A CN202180076999 A CN 202180076999A CN 116568289 A CN116568289 A CN 116568289A
Authority
CN
China
Prior art keywords
formulation
vardenafil
nasal
solubility
sildenafil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180076999.6A
Other languages
English (en)
Chinese (zh)
Inventor
摩西·周
谢乐尔·L·周
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Strategic Drug Solutions Co
Original Assignee
Strategic Drug Solutions Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Strategic Drug Solutions Co filed Critical Strategic Drug Solutions Co
Publication of CN116568289A publication Critical patent/CN116568289A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180076999.6A 2020-05-26 2021-12-01 治疗勃起功能障碍的配方和方法 Pending CN116568289A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063029881P 2020-05-26 2020-05-26
PCT/US2021/034334 WO2021242913A1 (en) 2020-05-26 2021-05-26 Formulations and methods for treating erectile dysfunction
USPCT/US2021/034334 2021-05-26
PCT/US2021/061488 WO2022250731A1 (en) 2020-05-26 2021-12-01 Formulations and methods for treating erectile dysfunction

Publications (1)

Publication Number Publication Date
CN116568289A true CN116568289A (zh) 2023-08-08

Family

ID=78722740

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180076999.6A Pending CN116568289A (zh) 2020-05-26 2021-12-01 治疗勃起功能障碍的配方和方法

Country Status (10)

Country Link
US (1) US20240216383A1 (cg-RX-API-DMAC7.html)
EP (1) EP4157449A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024521765A (cg-RX-API-DMAC7.html)
KR (1) KR20240013128A (cg-RX-API-DMAC7.html)
CN (1) CN116568289A (cg-RX-API-DMAC7.html)
AU (1) AU2021280285A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022024098A2 (cg-RX-API-DMAC7.html)
CA (1) CA3179630A1 (cg-RX-API-DMAC7.html)
IL (1) IL298432A (cg-RX-API-DMAC7.html)
WO (2) WO2021242913A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL247528B1 (pl) * 2023-04-08 2025-07-21 Sativa Med Spolka Akcyjna Płynna kompozycja inhibitorów fosfodiesterazy typu 5 (PDE-5), sposób jej wytwarzania oraz jej zastosowanie do leczenia zaburzeń erekcji

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3048501A (en) * 1999-11-18 2001-05-30 Natco Pharma Limited An improved pharmaceutical composition for treating male erectile dysfunction
DE10118306A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
US20060051413A1 (en) * 2004-09-08 2006-03-09 Chow Sing S M Method of enhancing absorptions of transmucosal administration formulations
DE102005009240A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
US20060207596A1 (en) * 2005-03-18 2006-09-21 Fairfield Clinical Trials, Llc Device and method for delivery of combination nasal medication
US8911751B2 (en) 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
MX2010004265A (es) * 2007-10-19 2010-07-28 Innozen Inc Composicion para administrar un ingrediente activo y metodo para hacer y usar el mismo.
GB2497933B (en) * 2011-12-21 2014-12-24 Londonpharma Ltd Drug delivery technology
US20140271847A1 (en) * 2013-03-13 2014-09-18 SatisPharma, LLC Formulations and methods for rapid penile erections
US20170014417A1 (en) * 2015-07-14 2017-01-19 Lipp Life Sciences Llc Pharmaceutical administration system for the transdermal application of vardenafil
CN111655229A (zh) 2017-12-20 2020-09-11 卡里亚制药控股有限公司 包含伐地那非的薄膜制剂、其制备方法及其用途
CA3105187A1 (en) * 2018-06-28 2020-01-02 Arx, Llc Dispensing method for producing dissolvable unit dose film constructs

Also Published As

Publication number Publication date
IL298432A (en) 2023-01-01
CA3179630A1 (en) 2021-12-02
BR112022024098A2 (pt) 2023-02-07
JP2024521765A (ja) 2024-06-04
WO2021242913A1 (en) 2021-12-02
US20240216383A1 (en) 2024-07-04
EP4157449A4 (en) 2024-05-29
EP4157449A1 (en) 2023-04-05
WO2022250731A1 (en) 2022-12-01
AU2021280285A1 (en) 2023-02-02
KR20240013128A (ko) 2024-01-30

Similar Documents

Publication Publication Date Title
US12144808B2 (en) Compositions and methods
ES2535233T3 (es) Pulverización de fentanilo sublingual
EP3639813B1 (en) A liquid formulation comprising nicotine for aerosol administration
ES2620413T3 (es) Formulaciones veterinarias antihelmínticas tópicas
AU2008282743B2 (en) Sublingual fentanyl spray
ES2664776T3 (es) Composición farmacéutica anticonvulsiva transnasal que comprende anticonvulsivo poco soluble
ES2611995T3 (es) Métodos y composiciones para el suministro de un agente terapéutico
US20130095174A1 (en) Compositions and Methods for Transmucosal Delivery of Lofexidine
Al-Ghananeem et al. Effect of pH on sublingual absorption of oxycodone hydrochloride
JP2024521765A (ja) 勃起不全を治療するための製剤および方法
CA2391968A1 (en) An improved pharmaceutical composition for treating male erectile dysfunction
US9737526B2 (en) Methods for treating Parkinson's disease
US12324811B2 (en) Intranasal formulation
HK40098632A (en) Formulations and methods for treating erectile dysfunction
KR20090081381A (ko) 경비 항경련성 약학 조성물
CN1977846A (zh) 治疗阳痿的药物组合物
Park et al. Can currently available drugs for erectile dysfunction be re-formulated to achieve rapid effect?
CN101484132A (zh) 具有合意口味的雷尼替丁制剂
WO2026043819A1 (en) Formulations and methods for convenient and rapid diuresis for the treatment of edema
JPWO2004087148A1 (ja) 肺疾患の治療および/または予防剤
CN118871101A (zh) 帕金森病治疗剂的改进的鼻施用
CN112996488A (zh) 唑吡坦或其药学上可接受的盐的口粘膜溶液

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40098632

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination